Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Crinetics Pharmaceuticals, Inc. (CRNX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/25/2022 |
8-K
| Quarterly results |
| 03/30/2022 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"CRINETICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED FINANCIAL STATEMENT DATA Three months ended December 31, Twelve months ended December 31, STATEMENTS OF OPERATIONS DATA: 2021 2020 2021 2020 License revenues $ 1,078 $ — $ 1,078 $ — Grant revenues — — — 71 Total revenues 1,078 — 1,078 71 Operating expenses: Research and development 24,604 16,830 84,255 56,998 General and administrative 7,362 4,961 24,525 18,026 Total operating expenses 31,966 21,791 108,780 75,024 Loss from operations Total other income , net 94 150 61 1,141 Net loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted-average shares - basic and diluted 45,229 32,952 38,436 30,448 BALANCE SHEET DATA: December 31, 2021 December 31, 2020 Cash, cash equivalents and investments $ 333,707 $ 170,880 Working cap...",
"X X X X X" |
|
| 09/15/2021 |
8-K
| Quarterly results |
| 10/26/2020 |
8-K
| Investor presentation |
| 04/06/2020 |
8-K
| Investor presentation |
| 10/01/2018 |
8-K
| Quarterly results |
|
|